Additionally, not addressed in this manuscript is the possible reduction in NRF2 activation and, consequently, HO-1 expression in cancer cells by bromodomain inhibitors, since NRF2 has been shown to be essential for pancreatic cancer initiation and progression [50,51]. The gene discussed is NFE2L2; the disease is cancer.